Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
120.26B | 117.76B | 106.37B | 92.87B | 83.06B | 77.16B | Gross Profit |
120.26B | 117.76B | 106.37B | 92.87B | 83.06B | 77.16B | EBIT |
3.34B | 2.56B | 4.01B | 3.80B | 3.15B | 4.99B | EBITDA |
4.12B | 3.53B | 4.93B | 4.64B | 3.86B | 5.60B | Net Income Common Stockholders |
1.71B | 1.21B | 2.49B | 2.81B | 2.93B | 3.37B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
22.14B | 20.43B | 21.32B | 5.06B | 3.39B | 4.67B | Total Assets |
50.93B | 46.48B | 47.06B | 43.05B | 44.36B | 34.97B | Total Debt |
13.31B | 11.72B | 11.66B | 11.42B | 12.82B | 6.98B | Net Debt |
9.06B | 9.50B | 6.96B | 6.36B | 9.43B | 2.31B | Total Liabilities |
33.11B | 30.03B | 30.75B | 9.03B | 10.54B | 6.06B | Stockholders Equity |
17.75B | 16.38B | 16.26B | 15.31B | 16.08B | 13.73B |
Cash Flow | Free Cash Flow | ||||
2.38B | 2.39B | 2.98B | 3.47B | 946.00M | 4.67B | Operating Cash Flow |
2.87B | 2.97B | 3.98B | 4.59B | 2.26B | 5.64B | Investing Cash Flow |
-2.22B | -2.95B | -3.49B | -1.01B | -6.56B | -3.06B | Financing Cash Flow |
-2.31B | -2.49B | -856.00M | -1.91B | 3.02B | -1.96B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $27.48B | 8.22 | 12.59% | ― | 8.85% | 33.30% | |
76 Outperform | $16.16B | 14.40 | 26.72% | ― | 16.71% | 12.23% | |
73 Outperform | $48.26B | 26.93 | 8.90% | 2.15% | 2.16% | 43.24% | |
72 Outperform | $28.39B | 16.63 | 10.09% | 1.50% | 10.09% | -12.18% | |
64 Neutral | $40.16B | ― | -414.62% | ― | 17.21% | 21.16% | |
54 Neutral | $5.37B | 3.26 | -45.10% | 3.30% | 16.81% | 0.02% | |
53 Neutral | $10.47B | ― | -21.25% | 5.38% | -6.88% | -6809.78% |
Humana Inc. announced that its senior management will meet with investors and analysts throughout June 2025 to reaffirm its earnings guidance for the year ending December 31, 2025. The company projects diluted earnings per share of approximately $14.68 and adjusted earnings per share of approximately $16.25, consistent with its previous guidance. Humana will also host an Investor Conference on June 16, 2025, to discuss its strategic direction and financial performance. The use of Adjusted EPS, which differs from GAAP EPS, is intended to provide a more comprehensive view of the company’s core operating performance.
The most recent analyst rating on (HUM) stock is a Hold with a $253.00 price target. To see the full list of analyst forecasts on Humana stock, see the HUM Stock Forecast page.
On May 30, 2025, Humana Inc. entered into a $5.0 billion unsecured revolving credit agreement with several banks, increasing its previous credit commitment from $2.642 billion. This new agreement replaces an expired $2.1 billion credit agreement and includes provisions for interest rates, facility fees, and covenants, allowing for up to $1.0 billion in incremental commitments. As of the agreement date, Humana had no outstanding borrowings and maintained approximately $4.98 billion in borrowing capacity, which could significantly impact its financial flexibility and operational strategy.
The most recent analyst rating on (HUM) stock is a Hold with a $253.00 price target. To see the full list of analyst forecasts on Humana stock, see the HUM Stock Forecast page.
Humana Inc. reported its financial results for the first quarter of 2025, noting a GAAP earnings per share (EPS) of $10.30 and an adjusted EPS of $11.58. The company affirmed its full-year 2025 adjusted EPS guidance of approximately $16.25, while revising its GAAP EPS guidance to approximately $14.68. Despite an anticipated decline in individual Medicare Advantage membership, Humana remains confident in its pricing strategy and long-term value creation. The company also highlighted progress in its CenterWell and Medicaid businesses, including a new contract in Illinois for a dual eligible special needs plan program.